Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C
Department of Haematology, CMC Hospital, Vellore, India.
Haemophilia. 1998 Jul;4(4):474-80. doi: 10.1046/j.1365-2516.1998.440474.x.
The problems with management of haemophilia in developing countries are poor awareness, inadequate diagnostic facilities and scarce factor concentrates for therapy. The priorities in establishing services for haemophilia include training care providers, setting up care centres, initiating a registry, educating affected people and their families about the condition, providing low-cost factor concentrates, improving social awareness and developing a comprehensive care team. A coagulation laboratory capable of reliably performing clotting times with correction studies using normal pooled, FVIII and FIX deficient patient plasma and factor assay is most essential for diagnosis. More advanced centralized laboratories are also needed. Molecular biology techniques for mutation detection and gene tracking should be established in each country for accurate carrier detection and antenatal diagnosis. Different models of haemophilia care exists. In India, there is no support from the government. Services, including import of factor concentrates, are organized by the Haemophilia Federation of India, with support from other institutions. Haemophilia is managed with minimal replacement therapy (about 2000 i.u./PWH/year). In Malaysia, where the system is fully supported by the government, facilities are available at all public hospitals and moderate levels of factor concentrates are available 'on-demand' (about 11,000 i.u./PWH/year) at the hospitals. Haemophilia care in South Africa is provided through major public hospitals. Intermediate purity factor concentrates are locally produced (about 12,000 i.u./PWH/year) at low cost. The combined experience in the developing world in providing haemophilia services should be used to define standards for care and set achievable goals.
发展中国家血友病管理存在的问题包括认知度低、诊断设施不足以及治疗用的凝血因子浓缩剂稀缺。建立血友病服务的优先事项包括培训护理人员、设立护理中心、启动登记系统、对患者及其家属进行疾病教育、提供低成本的凝血因子浓缩剂、提高社会认知度以及组建综合护理团队。一个能够使用正常混合血浆、FVIII和FIX缺乏患者血浆可靠地进行凝血时间及纠正研究以及因子测定的凝血实验室对于诊断最为关键。还需要更先进的中央实验室。每个国家都应建立用于突变检测和基因追踪的分子生物学技术,以进行准确的携带者检测和产前诊断。存在不同的血友病护理模式。在印度,政府不提供支持。包括凝血因子浓缩剂进口在内的服务由印度血友病联盟在其他机构的支持下组织开展。血友病通过最低限度的替代疗法进行管理(约2000国际单位/每年/每例血友病患者)。在马来西亚,该系统得到政府的全力支持,所有公立医院都有相关设施,医院可“按需”提供中等水平的凝血因子浓缩剂(约11,000国际单位/每年/每例血友病患者)。南非的血友病护理通过主要公立医院提供。中等纯度的凝血因子浓缩剂在当地以低成本生产(约12,000国际单位/每年/每例血友病患者)。发展中世界在提供血友病服务方面的综合经验应用于确定护理标准并设定可实现的目标。